{"id":"gsk1838262-extended-release-tablets","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disorders (diarrhea, nausea)"},{"rate":null,"effect":"Osmotic diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SGLT1 is responsible for active glucose transport across the intestinal epithelium. By inhibiting SGLT1, GSK1838262 decreases postprandial glucose levels and overall glucose absorption. This mechanism is distinct from SGLT2 inhibitors, which work primarily in the kidney, and may provide therapeutic benefit in glycemic control with a different safety profile.","oneSentence":"GSK1838262 is a selective inhibitor of sodium-dependent glucose cotransporter 1 (SGLT1) that reduces intestinal glucose absorption.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:14:43.241Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT00748098","phase":"PHASE3","title":"Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance","status":"COMPLETED","sponsor":"XenoPort, Inc.","startDate":"2008-10","conditions":"Restless Legs Syndrome, Restless Legs Syndrome (RLS)","enrollment":136}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["XP13512","gabapentin enacarbil"],"phase":"phase_3","status":"active","brandName":"GSK1838262 Extended Release Tablets","genericName":"GSK1838262 Extended Release Tablets","companyName":"XenoPort, Inc.","companyId":"xenoport-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GSK1838262 is a selective inhibitor of sodium-dependent glucose cotransporter 1 (SGLT1) that reduces intestinal glucose absorption. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}